Concepts (112)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Arteries | 4 | 2009 | 67 | 1.200 |
Why?
|
| C-Reactive Protein | 1 | 2021 | 147 | 0.750 |
Why?
|
| Blood Pressure | 5 | 2014 | 613 | 0.590 |
Why?
|
| Menarche | 1 | 2015 | 13 | 0.530 |
Why?
|
| Cardiovascular Diseases | 4 | 2009 | 628 | 0.490 |
Why?
|
| Tunica Media | 3 | 2008 | 14 | 0.470 |
Why?
|
| Premature Birth | 2 | 2011 | 71 | 0.440 |
Why?
|
| Vascular Resistance | 3 | 2009 | 32 | 0.440 |
Why?
|
| Age Factors | 2 | 2015 | 1007 | 0.430 |
Why?
|
| Tunica Intima | 2 | 2008 | 21 | 0.400 |
Why?
|
| Infant, Low Birth Weight | 2 | 2011 | 37 | 0.390 |
Why?
|
| Fetal Organ Maturity | 1 | 2010 | 3 | 0.380 |
Why?
|
| Adult | 14 | 2021 | 11034 | 0.350 |
Why?
|
| Louisiana | 5 | 2010 | 39 | 0.350 |
Why?
|
| Heterotrimeric GTP-Binding Proteins | 1 | 2008 | 10 | 0.330 |
Why?
|
| Bilirubin | 1 | 2008 | 17 | 0.330 |
Why?
|
| Carotid Artery Diseases | 1 | 2008 | 22 | 0.330 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2008 | 63 | 0.320 |
Why?
|
| Angiotensinogen | 1 | 2007 | 5 | 0.320 |
Why?
|
| Carotid Artery, Common | 1 | 2007 | 9 | 0.320 |
Why?
|
| Female | 17 | 2021 | 19873 | 0.290 |
Why?
|
| Pulsatile Flow | 1 | 2006 | 15 | 0.290 |
Why?
|
| Radial Artery | 2 | 2020 | 4 | 0.280 |
Why?
|
| Risk Factors | 9 | 2020 | 3414 | 0.280 |
Why?
|
| Humans | 19 | 2021 | 34853 | 0.260 |
Why?
|
| Femoral Artery | 2 | 2020 | 11 | 0.260 |
Why?
|
| Depression | 2 | 2021 | 664 | 0.250 |
Why?
|
| Compliance | 3 | 2009 | 9 | 0.240 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2007 | 638 | 0.240 |
Why?
|
| Longitudinal Studies | 2 | 2021 | 841 | 0.230 |
Why?
|
| Cholesterol, HDL | 2 | 2021 | 87 | 0.230 |
Why?
|
| Young Adult | 4 | 2021 | 4012 | 0.220 |
Why?
|
| Male | 12 | 2021 | 18870 | 0.220 |
Why?
|
| Carotid Arteries | 2 | 2015 | 29 | 0.210 |
Why?
|
| Quarantine | 1 | 2021 | 7 | 0.200 |
Why?
|
| Pregnancy Complications, Infectious | 2 | 2011 | 99 | 0.170 |
Why?
|
| Adolescent | 3 | 2021 | 5035 | 0.160 |
Why?
|
| Antiretroviral Therapy, Highly Active | 2 | 2011 | 219 | 0.160 |
Why?
|
| Mental Health | 1 | 2021 | 270 | 0.160 |
Why?
|
| Gene Frequency | 2 | 2008 | 155 | 0.160 |
Why?
|
| Myocardial Infarction | 1 | 2020 | 221 | 0.160 |
Why?
|
| Competitive Behavior | 1 | 2017 | 11 | 0.150 |
Why?
|
| Religion and Medicine | 1 | 2017 | 18 | 0.150 |
Why?
|
| Running | 1 | 2017 | 13 | 0.150 |
Why?
|
| Walking | 1 | 2017 | 64 | 0.140 |
Why?
|
| Genotype | 2 | 2008 | 641 | 0.140 |
Why?
|
| Tuberculosis | 1 | 2015 | 56 | 0.130 |
Why?
|
| Linear Models | 1 | 2015 | 253 | 0.120 |
Why?
|
| Anxiety | 1 | 2021 | 705 | 0.120 |
Why?
|
| Child | 1 | 2021 | 2875 | 0.110 |
Why?
|
| Retrospective Studies | 4 | 2011 | 1961 | 0.110 |
Why?
|
| Protease Inhibitors | 1 | 2011 | 47 | 0.100 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2014 | 160 | 0.100 |
Why?
|
| HIV Infections | 3 | 2011 | 2207 | 0.100 |
Why?
|
| United States | 1 | 2021 | 3894 | 0.100 |
Why?
|
| Birth Weight | 1 | 2011 | 93 | 0.100 |
Why?
|
| Pregnancy | 3 | 2011 | 1503 | 0.100 |
Why?
|
| Models, Biological | 1 | 2014 | 642 | 0.100 |
Why?
|
| New Orleans | 1 | 2010 | 11 | 0.100 |
Why?
|
| Infant, Newborn | 2 | 2011 | 871 | 0.090 |
Why?
|
| Muscle Tonus | 1 | 2009 | 6 | 0.090 |
Why?
|
| Middle Aged | 6 | 2020 | 9642 | 0.090 |
Why?
|
| Insurance Coverage | 1 | 2010 | 99 | 0.090 |
Why?
|
| Cesarean Section | 1 | 2009 | 53 | 0.090 |
Why?
|
| Postoperative Complications | 1 | 2009 | 206 | 0.080 |
Why?
|
| HTLV-II Infections | 1 | 2007 | 6 | 0.080 |
Why?
|
| Polymorphism, Genetic | 1 | 2008 | 165 | 0.080 |
Why?
|
| Lung | 1 | 2010 | 413 | 0.080 |
Why?
|
| HTLV-I Infections | 1 | 2007 | 31 | 0.080 |
Why?
|
| Ultrasonography | 1 | 2007 | 115 | 0.080 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2010 | 248 | 0.070 |
Why?
|
| Sex Factors | 1 | 2009 | 859 | 0.070 |
Why?
|
| Ultrasonography, Doppler | 1 | 2006 | 19 | 0.070 |
Why?
|
| Insulin Resistance | 1 | 2008 | 177 | 0.070 |
Why?
|
| Atherosclerosis | 1 | 2007 | 131 | 0.070 |
Why?
|
| Reference Values | 1 | 2006 | 204 | 0.070 |
Why?
|
| Cohort Studies | 1 | 2009 | 1422 | 0.070 |
Why?
|
| Health | 1 | 2005 | 28 | 0.070 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2008 | 528 | 0.070 |
Why?
|
| Mississippi | 2 | 2015 | 107 | 0.060 |
Why?
|
| Oxidative Stress | 1 | 2008 | 874 | 0.050 |
Why?
|
| HIV-1 | 1 | 2007 | 678 | 0.050 |
Why?
|
| Body Mass Index | 1 | 2005 | 775 | 0.050 |
Why?
|
| Hypertension | 1 | 2007 | 770 | 0.050 |
Why?
|
| Hemorrhage | 1 | 2020 | 46 | 0.050 |
Why?
|
| Cross-Sectional Studies | 1 | 2007 | 2561 | 0.050 |
Why?
|
| Aged | 2 | 2020 | 6448 | 0.040 |
Why?
|
| Treatment Outcome | 1 | 2020 | 1349 | 0.030 |
Why?
|
| Time Factors | 1 | 2020 | 1681 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2017 | 628 | 0.030 |
Why?
|
| Obesity, Abdominal | 1 | 2014 | 26 | 0.030 |
Why?
|
| Disease Outbreaks | 1 | 2015 | 155 | 0.030 |
Why?
|
| Triglycerides | 1 | 2014 | 129 | 0.030 |
Why?
|
| Motivation | 1 | 2017 | 415 | 0.030 |
Why?
|
| Urban Population | 1 | 2015 | 318 | 0.030 |
Why?
|
| Blood Glucose | 1 | 2014 | 333 | 0.030 |
Why?
|
| Aged, 80 and over | 1 | 2017 | 2333 | 0.020 |
Why?
|
| Chorioamnionitis | 1 | 2009 | 6 | 0.020 |
Why?
|
| Employment | 1 | 2010 | 73 | 0.020 |
Why?
|
| Morbidity | 1 | 2009 | 94 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2010 | 322 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2010 | 423 | 0.020 |
Why?
|
| Educational Status | 1 | 2010 | 295 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2009 | 528 | 0.020 |
Why?
|
| Genes, pX | 1 | 2007 | 3 | 0.020 |
Why?
|
| CD4-CD8 Ratio | 1 | 2007 | 28 | 0.020 |
Why?
|
| Gene Dosage | 1 | 2007 | 74 | 0.020 |
Why?
|
| Logistic Models | 1 | 2009 | 894 | 0.020 |
Why?
|
| Viral Load | 1 | 2007 | 300 | 0.020 |
Why?
|
| DNA, Viral | 1 | 2007 | 295 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2007 | 1353 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2007 | 1152 | 0.010 |
Why?
|